Review of Prospective Trials Assessing the Role of Stereotactic Body Radiation Therapy for Metastasis-directed Treatment in Oligometastatic Genitourinary Cancers

In this report, we looked at outcomes after stereotactic body radiation therapy (SBRT) for oligometastatic genitourinary cancers. We found that the most common and best-studied application of SBRT has been for oligorecurrent prostate cancer. However, much work remains to define SBRT alone compared with other standard of care treatments for prostate cancer, or the role of SBRT in tumor control or delaying time until next therapy in oligometastatic renal and bladder cancer.